Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 65862-626

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 65862-626). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

A Kaplan-Meier plot showing the estimated probability of achieving an initial headache response within 2 hours post-dose, comparing placebo, Rizatriptan Benzoate Tablets 5 mg, and Rizatriptan Benzoate Tablets 10 mg, based on pooled data from four outpatient studies.*

FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

A Kaplan-Meier plot showing the estimated probability of patients taking a second dose of Rizatriptan Benzoate Tablets 5 mg, 10 mg, or placebo for migraines over 24 hours after the initial dose, based on pooled data from four clinical trials. The graph plots probability of medication rescue on the vertical axis and hours post-dose on the horizontal axis.*

FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)

A Kaplan-Meier plot showing the estimated probability of achieving an initial headache response within 2 hours post-dose with Rizatriptan Benzoate orally disintegrating tablets at 5 mg and 10 mg doses compared to placebo. The graph displays increasing response probabilities over time in pooled studies.*

FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 5 And 6‡‡ (Rizatriptan Fig4)

A Kaplan-Meier plot showing the estimated probability of patients taking a second dose of Rizatriptan Benzoate orally disintegrating tablets at 5 mg and 10 mg strengths or other migraine medication within 24 hours after the initial dose. The graph compares placebo, 5 mg, and 10 mg tablets over time in pooled clinical studies.*

FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

A line graph showing the observed percentage of patients reporting no headache pain up to 2 hours after dosing in Study 7. It compares Rizatriptan Benzoate orally disintegrating tablets with placebo across time points 0.5, 1, 1.5, and 2 hours post-dose, with percentages on the y-axis. Rizatriptan shows a higher percentage of pain relief than placebo over time.*

FDA Label Image

Package Label-principal Display Panel (5 mg Unit-of-Use Pack (9 Tablets))

Packaging label for Rizatriptan Benzoate Orally Disintegrating Tablets, USP 5 mg by Aurobindo Pharma Limited. The label indicates the product contains 9 tablets (3 blister cards of 3 tablets each) with a child-resistant unit-of-use package. Additional storage and usage instructions are included along with distributor information for Aurobindo Pharma USA, Inc.*

FDA Label Image

Package Label-principal Display Panel (10 mg Unit-of-Use Pack (9 Tablets))

Label for Rizatriptan Benzoate Orally Disintegrating Tablets, USP, 5 mg strength. The package contains 9 tablets and is labeled as Rx only. Distributed by Aurobindo Pharma USA, Inc., made in India. Includes dosing information, phenylketonurics warning, storage instructions, and NDC 65862-625-36. The label also shows the Aurobindo logo.*

FDA Label Image

Rizatriptan Fig8

Packaging label for Rizatriptan Benzoate Orally Disintegrating Tablets, USP, 10 mg strength. The label states the product contains 9 tablets divided into 3 blister cards of 3 tablets each. It is marked Rx only and includes storage instructions, phenylketonurics warning, and distributor information for Aurobindo Pharma USA, Inc. The label features the Aurobindo logo and barcode.*

FDA Label Image

Rizatriptan Fig9

Label for Rizatriptan Benzoate Orally Disintegrating Tablets, USP, 10 mg, showing a package of 9 tablets. The label includes RX only status, distributor information for Aurobindo Pharma USA, and storage instructions. It specifies that each tablet contains 14.53 mg of rizatriptan benzoate equivalent to 10 mg rizatriptan and mentions phenylketonurics content.*

FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical structure diagram of Rizatriptan Benzoate, depicting the molecular arrangement of the active ingredient as typically seen in pharmaceutical labeling and documentation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.